Calibrite Display Plus HL Receives Apple Approval for Hardware-Level Display Calibration For the first time, creative professionals can calibrate Apple displays at hardware… CISION PRNewswireJune 1, 2026
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept First-line NSCLC – Compelling Activity Across All PD-L1 SubgroupsIn first-line non-small cell… CISION PRNewswireJune 1, 2026
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting SHANGHAI, June 1, 2026 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code:… CISION PRNewswireJune 1, 2026
BusinessPress ReleaseMICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026 TAIPEI, June 1, 2026 /PRNewswire/ — MICROIP (TPEx: 7796), specializing in AI… CISION PRNewswireJune 1, 2026
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview TAIPEI, June 1, 2026 /PRNewswire/ — Jyong Biotech Ltd. (Nasdaq: MENS) (the… CISION PRNewswireJune 1, 2026
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4… CISION PRNewswireJune 1, 2026
Press ReleaseImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO SUZHOU, China, June 1, 2026 /PRNewswire/ — ImmVira Group ("ImmVira") today announced… CISION PRNewswireJune 1, 2026
Press Release2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety… CISION PRNewswireJune 1, 2026
